Earlier this month (July 10, 2026), the German government voted through a sweeping set of provisions set to significantly impact medical cannabis patients who have their prescriptions covered by their statutory health insurance.
With Aurora Cannabis and High Tide consolidating their presence across Europe, with a focus on Germany, how will this lucrative supply chain be impacted by shifting geopolitical dynamics?
Written by Ben Stevens and Sarah Sinclair. You can read Part 1 here.
Written by Ben Stevens and Sarah Sinclair. 2024 has been a dramatic year for the global cannabis industry, seeing both historic steps forward and concerning regressions in both attitudes and policy.
In a landmark moment for the Greek medical cannabis industry, Tikun Olam Europe, the 1st Medical Cannabis Company in Greece, sets new standards and achieves another first by completing the 1st export of finished medical cannabis products from Greece
Earlier this year, Greece became the latest EU country to make medical cannabis products available to patients.
As part of its European expansion, CBD of Denver has announced that its wholly owned subsidiary, Luxora, has signed four Letters of Intent (LoI) to build production facilities for four Cannabis Clubs in Germany.
The European CBD Report: Health & Wellness has been published by Prohibition Partners and sponsored by Atalis.
The companies have stated the LOI positions each to take advantage of potential German adult use legalisation within their respective supply chain verticals.
